Icon Partners with Taiwanese University to Further Trial Advancements

By Zachary Brennan

- Last updated on GMT

Icon teams with Taiwan Hospital
Icon teams with Taiwan Hospital

Related tags Clinical trial

CRO momentum in Asia is picking up as Icon has partnered with a clinical research centre at the National Taiwan University Hospital to accelerate drug development on the Chinese island.

Under the terms of the agreement, the National Clinical Trials Research Centre (NCTRC) and Icon will collaborate on study start-up, site feasibility, key site and investigator selection and patient recruitment. 

This is a long-term commitment between Icon and NCTRC​,” Wei Ming Goh, VP of Icon’s Asia-Pacific division, told Outsourcing-Pharma.com. “Icon already has a strong position in Asia, with operations in 13 countries…we can further accelerate timelines for study start-up and patient recruitment which will benefit our customers and also enhance the Taiwanese clinical trials industry​.”

Icon isn’t the first CRO to set up shop in Taiwan. US CRO Chiltern set up its own legal entity​ on the island in 2012 because client demand was so high, while QPS formed a joint venture​ to take a stab at the region and Parexel purchased a Taiwanese firm​ back in 2007.

Almost two years ago, six Asian CROs, including Taiwan’s StatPlus​, also formed an alliance to compete with the Western CROs operating in the region.

Icon Partnership Details

As far as what the partnership will specifically focus on, there does not seem to be one dominant type of clinical trial or therapeutic area.

This collaboration is not limited to any particular therapeutic area​,” Goh said. “The 10 leading causes of death in Taiwan are cancer, heart disease, cerebrovascular disease, pneumonia, diabetes, accidents, lower respiratory illness, hypertensive disease, chronic liver disease, and nephrotic syndrome and nephritis​. 

Due to the prevalence of these diseases and consequently the access to patients, studies associated with these therapeutic areas may be more prevalent than others​,” he added.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more